Down syndrome (DS) is one of the most commonly occurring chromosomal conditions. Most individuals with DS develop Alzheimer’s disease (AD) by 50 years of age. Recent evidence suggests that AD pathology in the locus coeruleus (LC) is an early event in sporadic AD. It is likely that the widespread axonal network of LC neurons contributes to the spread of tau pathology in the AD brain, although this has not been investigated in DS-AD.
Objective:
The main purpose of this study was to profile AD pathology and neuroinflammation in the LC, comparing AD and DS-AD in postmortem human tissues.
Methods:
We utilized immunofluorescence and semi-quantitative analyses of pTau (4 different forms), amyloid-β (Aβ), glial, and neuronal markers in the LC across 36 cases (control, DS-AD, and AD) to compare the different pathological profiles.
Results:
Oligomeric tau was highly elevated in DS-AD cases compared to LOAD or EOAD cases. The distribution of staining for pT231 was elevated in DS-AD and EOAD compared to the LOAD group. The DS-AD group exhibited increased Aβ immunostaining compared to AD cases. The number of tau-bearing neurons was also significantly different between the EOAD and DS-AD cases compared to the LOAD cases.
Conclusions:
While inflammation, pTau, and Aβ are all involved in AD pathology, their contribution to disease progression may differ depending on the diagnosis. Our results suggest that DS-AD and EOAD may be more similar in pathology than LOAD. Our study highlights unique avenues to further our understanding of the mechanisms governing AD neuropathology.
PlaiasuV. Down syndrome - genetics and cardiogenetics. Maedica (Bucur)2017; 12: 208–213.
2.
AntonarakisSE, SkotkoBG, RafiiMS, et al. Down syndrome. Nat Rev Dis Primers2020; 6: 9.
3.
FarrellC, MumfordP and WisemanFK. Rodent modeling of Alzheimer’s disease in Down syndrome: in vivo and ex vivo approaches. Front Neurosci2022; 16: 909669.
4.
LejeuneJ, GautierM and TurpinR. Study of somatic chromosomes from 9 mongoloid children. C R Hebd Seances Acad Sci1959; 248: 1721–1722.
5.
van TrotsenburgAS, HeymansHS, TijssenJG, et al. Comorbidity, hospitalization, and medication use and their influence on mental and motor development of young infants with Down syndrome. Pediatrics2006; 118: 1633–1639.
6.
BenhaourechS, DrighilA and HammiriAE. Congenital heart disease and Down syndrome: various aspects of a confirmed association. Cardiovasc J Afr2016; 27: 287–290.
7.
RafiiMS, KleschevnikovAM, SawaM, et al. Down syndrome. Handb Clin Neurol2019; 167: 321–336.
8.
WisniewskiKE, DaltonAJ, McLachlanC, et al. Alzheimer’s disease in Down’s syndrome: clinicopathologic studies. Neurology1985; 35: 957–961.
9.
DavidsonYS, RobinsonA, PrasherVP, et al. The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome. Acta Neuropathol Commun2018; 6: 56.
10.
GomesFC, MattosMF, Goloni-BertolloEM, et al. Alzheimer’s disease in the Down syndrome: an overview of genetics and molecular aspects. Neurol India2021; 69: 32–41.
11.
SnyderHM, BainLJ, BrickmanAM, et al. Further understanding the connection between Alzheimer’s disease and Down syndrome. Alzheimers Dement2020; 16: 1065–1077.
12.
LloretA, BadiaMC, GiraldoE, et al. Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer’s disease. J Alzheimers Dis2011; 27: 701–709.
13.
GulesserianT, SeidlR, HardmeierR, et al. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med2001; 49: 41–46.
14.
DuchonA and HeraultY. DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in Down syndrome. Front Behav Neurosci2016; 10: 104.
15.
RyooSR, JeongHK, RadnaabazarC, et al. DYRK1A-mediated hyperphosphorylation of tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem2007; 282: 34850–34857.
16.
ForteaJ, VilaplanaE, Carmona-IraguiM, et al. Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet2020; 395: 1988–1997.
17.
StrydomA, CoppusA, BlesaR, et al. Alzheimer’s disease in Down syndrome: An overlooked population for prevention trials. Alzheimers Dement (N Y)2018; 4: 703–713.
18.
HartleyD, BlumenthalT, CarrilloM, et al. Down syndrome and Alzheimer’s disease: Common pathways, common goals. Alzheimers Dement2015; 11: 700–709.
19.
MendezMF. Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn)2019; 25: 34–51.
ChaudhuryS, PatelT, BarberIS, et al. Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer’s disease. Neurobiol Aging2018; 62: 244e241–244e248.
22.
AyodeleT, RogaevaE, KurupJT, et al. Early-onset Alzheimer’s disease: what is missing in research?Curr Neurol Neurosci Rep2021; 21: 4.
23.
ReitzC and MayeuxR. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol2014; 88: 640–651.
24.
PalasíA, Gutiérrez-IglesiasB, AlegretM, et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold?J Neurol2015; 262: 1238–1246.
25.
MontufarS, CaleroC, VinuezaR, et al. Association between the APOE epsilon4 allele and late-onset Alzheimer’s disease in an Ecuadorian Mestizo population. Int J Alzheimers Dis2017; 2017: 1059678.
26.
Trejo-LopezJA, YachnisAT and ProkopS. Neuropathology of Alzheimer’s disease. Neurotherapeutics2022; 19: 173–185.
27.
ThalDR, RübU, OrantesM, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology2002; 58: 1791–1800.
28.
BraakH and BraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
29.
PutraP, ThompsonTB, ChaggarP, et al. Braiding Braak and Braak: Staging patterns and model selection in network neurodegeneration. Netw Neurosci2021; 5: 929–956.
30.
BraakH, ThalDR, GhebremedhinE, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol2011; 70: 960–969.
31.
VogelJW, Iturria-MedinaY, StrandbergOT, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat Commun2020; 11: 2612.
32.
Andres-BenitoP, Fernandez-DuenasV, CarmonaM, et al. Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathol Appl Neurobiol2017; 43: 373–392.
33.
RorabaughJM, ChalermpalanupapT, Botz-ZappCA, et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease. Brain2017; 140: 3023–3038.
34.
ChenY, ChenT and HouR. Locus coeruleus in the pathogenesis of Alzheimer’s disease: A systematic review. Alzheimers Dement (N Y)2022; 8: e12257.
35.
GiorgiFS, SaccaroLF, GalganiA, et al. The role of locus coeruleus in neuroinflammation occurring in Alzheimer’s disease. Brain Res Bull2019; 153: 47–58.
36.
GrinbergLT, RübU, FerrettiRE, et al. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?Neuropathol Appl Neurobiol2009; 35: 406–416.
37.
SimicG, StanicG, MladinovM, et al. Does Alzheimer’s disease begin in the brainstem?Neuropathol Appl Neurobiol2009; 35: 532–554.
38.
VogelJW, YoungAL, OxtobyNP, et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med2021; 27: 871–881.
39.
Breton-ProvencherV, DrummondGT and SurM. Locus coeruleus norepinephrine in learned behavior: anatomical modularity and spatiotemporal integration in targets. Front Neural Circuits2021; 15: 638007.
40.
SchwarzLA and LuoL. Organization of the locus coeruleus-norepinephrine system. Curr Biol2015; 25: R1051–R1056.
41.
JamesT, KulaB, ChoiS, et al. Locus coeruleus in memory formation and Alzheimer’s disease. Eur J Neurosci2021; 54: 6948–6959.
42.
TsukaharaJS and EngleRW. Fluid intelligence and the locus coeruleus-norepinephrine system. Proc Natl Acad Sci U S A2021; 118.
43.
TheofilasP, EhrenbergAJ, NguyA, et al. Probing the correlation of neuronal loss, neurofibrillary tangles, and cell death markers across the Alzheimer’s disease Braak stages: a quantitative study in humans. Neurobiol Aging2018; 61: 1–12.
44.
HenekaMT, GaleaE, GavriluykV, et al. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer’s disease. J Neurosci2002; 22: 2434–2442.
45.
WeinshenkerD. Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res2008; 5: 342–345.
46.
HenekaMT, NadrignyF, RegenT, et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A2010; 107: 6058–6063.
47.
HenekaMT, RamanathanM, JacobsAH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci2006; 26: 1343–1354.
48.
LynessSA, ZarowC and ChuiHC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging2003; 24: 1–23.
49.
SimicG, Babic LekoM, WrayS, et al. Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol2017; 151: 101–138.
50.
SullivanKD, LewisHC, HillAA, et al. Trisomy 21 consistently activates the interferon response. Elife2016; 5.
51.
RamG and ChinenJ. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol2011; 164: 9–16.
52.
WilcockDM and GriffinWS. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation2013; 10: 84.
53.
WilcockDM, HurbanJ, HelmanAM, et al. Down syndrome individuals with Alzheimer’s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer’s disease. Neurobiol Aging2015; 36: 2468–2474.
54.
WilcockDM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer’s disease. Curr Gerontol Geriatr Res2012; 2012: 170276.
55.
Flores-AguilarL, IulitaMF, KovecsesO, et al. Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain2020; 143: 3653–3671.
56.
AlldredMJ, MartiniAC, PattersonD, et al. Aging with Down syndrome-where are we now and where are we going?J Clin Med2021; 10: 4687.
57.
LockrowJP, FortressAM and GranholmAC. Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res2012; 2012: 463909.
58.
IulitaMF, Garzon ChavezD, Klitgaard ChristensenM, et al. Association of Alzheimer disease with life expectancy in people with Down syndrome. JAMA Netw Open2022; 5: e2212910.
59.
AdlerL, TanakaY, WilliamsD, et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol2014; 34: 461–466.
60.
Ince TasdelenB, KarakayaE and OztopDB. Effects of atomoxetine and osmotic release oral system-methylphenidate on executive functions in patients with combined type attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol2015; 25: 494–500.
61.
XiaY, ProkopS and GiassonBI. “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol Neurodegener2021; 16: 37.
62.
KimuraT, SharmaG, IshiguroK, et al. Phospho-tau bar code: analysis of phosphoisotypes of tau and its application to tauopathy. Front Neurosci2018; 12: 44.
63.
JackCRJr, BennettDA, BlennowK, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
64.
Alelu-PazR, Iturrieta-ZuazoI, ByneW, et al. A new antigen retrieval technique for human brain tissue. PLoS One2008; 3: e3378.
65.
LeongAS and HaffajeeZ. Citraconic anhydride: a new antigen retrieval solution. Pathology2010; 42: 77–81.
66.
SchindelinJ, Arganda-CarrerasI, FriseE, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods2012; 9: 676–682.
67.
RuedenCT, SchindelinJ, HinerMC, et al. ImageJ ImageJ for the next generation of scientific image data. BMC Bioinformatics2017; 18: 529.
68.
GoberR, ArdalanM, ShiadehSMJ, et al. Microglia activation in postmortem brains with schizophrenia demonstrates distinct morphological changes between brain regions. Brain Pathol2022; 32: e13003.
69.
GriffinP, ApostolovaL, DickersonBC, et al. Developments in understanding early onset Alzheimer’s disease. Alzheimers Dement2023; 19(Suppl 9): S126–S131.
70.
Graff-RadfordJ, YongKXX, ApostolovaLG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol2021; 20: 222–234.
71.
ParizotE, DardR, JanelN, et al. Down syndrome and infertility: what support should we provide?J Assist Reprod Genet2019; 36: 1063–1067.
72.
WangY, ZhangY, HuW, et al. Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation. Sci Rep2015; 5: 15709.
73.
MatsuoES, ShinRW, BillingsleyML, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron1994; 13: 989–1002.
74.
LiJ, GouldTD, YuanP, et al. Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology2003; 28: 1017–1025.
75.
BlairJA, WangC, HernandezD, et al. Individual case analysis of postmortem interval time on brain tissue preservation. PLoS One2016; 11: e0151615.
76.
JoyceJN, SmutzerG, WhittyCJ, et al. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease. Mov Disord1997; 12: 885–897.
77.
McMillanPJ, WhiteSS, FranklinA, et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s disease. Brain Res2011; 1373: 240–252.
78.
PorteliusE, BrinkmalmG, TranAJ, et al. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis2009; 6: 87–94.
79.
ShojiM, GoldeTE, GhisoJ, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science1992; 258: 126–129.
80.
Gallego VillarejoL, BachmannL, MarksD, et al. Role of intracellular amyloid beta as pathway modulator, biomarker, and therapy target. Int J Mol Sci2022; 23: 4656.
81.
DongH and CsernanskyJG. Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis2009; 18: 459–469.
82.
WardSM, HimmelsteinDS, LanciaJK, et al. TOC characterization of a selective oligomeric tau antibody. J Alzheimers Dis2013; 37: 593–602.
83.
VossK, KorenJ3rd and DickeyCA. The earliest tau dysfunction in Alzheimer’s disease? Tau phosphorylated at s422 as a toxic seed. Am J Pathol2011; 179: 2148–2151.
84.
Luna-MunozJ, Garcia-SierraF, FalconV, et al. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer’s disease. J Alzheimers Dis2005; 8: 29–41.
85.
NeddensJ, TemmelM, FlunkertS, et al. Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun2018; 6: 52.
86.
MoloneyCM, LoweVJ and MurrayME. Visualization of neurofibrillary tangle maturity in Alzheimer’s disease: A clinicopathologic perspective for biomarker research. Alzheimers Dement2021; 17: 1554–1574.
87.
BraakE, BraakH and MandelkowEM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol1994; 87: 554–567.
88.
UchiharaT. Pretangles and neurofibrillary changes: similarities and differences between AD and CBD based on molecular and morphological evolution. Neuropathology2014; 34: 571–577.
89.
LaceG, SavvaGM, ForsterG, et al. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain2009; 132: 1324–1334.
90.
UematsuM, NakamuraA, EbashiM, et al. Brainstem tau pathology in Alzheimer’s disease is characterized by increase of three repeat tau and independent of amyloid beta. Acta Neuropathol Commun2018; 6: 1.
91.
AugustinackJC, SchneiderA, MandelkowEM, et al. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol2002; 103: 26–35.
92.
KitamuraT, SugimoriK, SudoS, et al. Relationship between microtubule-binding repeats and morphology of neurofibrillary tangle in Alzheimer’s disease. Acta Neurol Scand2005; 112: 327–334.
93.
Vidal-ItriagoA, RadfordRAW, AramidehJA, et al. Microglia morphophysiological diversity and its implications for the CNS. Front Immunol2022; 13: 997786.
94.
MartiniAC, HelmanAM, McCartyKL, et al. Distribution of microglial phenotypes as a function of age and Alzheimer’s disease neuropathology in the brains of people with Down syndrome. Alzheimers Dement (Amst)2020; 12: e12113.
95.
BocheD and GordonMN. Diversity of transcriptomic microglial phenotypes in aging and Alzheimer’s disease. Alzheimers Dement2022; 18: 360–376.
96.
PaolicelliRC, SierraA, StevensB, et al. Microglia states and nomenclature: A field at its crossroads. Neuron2022; 110: 3458–3483.
97.
DavisBM, Salinas-NavarroM, CordeiroMF, et al. Characterizing microglia activation: a spatial statistics approach to maximize information extraction. Sci Rep2017; 7: 1576.
98.
PremanP, Alfonso-TrigueroM, AlberdiE, et al. Astrocytes in Alzheimer’s disease: pathological significance and molecular pathways. Cells2021; 10: 540.
99.
KellySC, HeB, PerezSE, et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol Commun2017; 5: 8.
100.
FernandesP, RegalaJ, CorreiaF, et al. The human locus coeruleus 3-D stereotactic anatomy. Surg Radiol Anat2012; 34: 879–885.
101.
GermanDC, WalkerBS, ManayeK, et al. The human locus coeruleus: computer reconstruction of cellular distribution. J Neurosci1988; 8: 1776–1788.
102.
OlivieriP, LagardeJ, LehericyS, et al. Early alteration of the locus coeruleus in phenotypic variants of Alzheimer’s disease. Ann Clin Transl Neurol2019; 6: 1345–1351.
103.
TheofilasP, EhrenbergAJ, DunlopS, et al. Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement2017; 13: 236–246.
104.
WisemanFK, PulfordLJ, BarkusC, et al. Trisomy of human chromosome 21 enhances amyloid-beta deposition independently of an extra copy of APP. Brain2018; 141: 2457–2474.
105.
DoranE, KeatorD, HeadE, et al. Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J Alzheimers Dis2017; 56: 459–470.
106.
TellerJK, RussoC, DeBuskLM, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down’s syndrome. Nat Med1996; 2: 93–95.
107.
RussoC, SaidoTC, DeBuskLM, et al. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer’s disease and Down’s syndrome brains. FEBS Lett1997; 409: 411–416.
108.
WisniewskiKE, WisniewskiHM and WenGY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol1985; 17: 278–282.
109.
HeadE, LottIT, WilcockDM, et al. Aging in Down syndrome and the development of Alzheimer’s disease neuropathology. Curr Alzheimer Res2016; 13: 18–29.
110.
NistorM, DonM, ParekhM, et al. Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. Neurobiol Aging2007; 28: 1493–1506.
111.
BaumLW. Sex, hormones, and Alzheimer’s disease. J Gerontol A Biol Sci Med Sci2005; 60: 736–743.
112.
AlmeidaOP, WaterreusA, SpryN, et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology2004; 29: 1071–1081.
113.
LeiY and RenyuanZ. Effects of androgens on the amyloid-beta protein in Alzheimer’s disease. Endocrinology2018; 159: 3885–3894.
114.
GamacheJ, YunY and Chiba-FalekO. Sex-dependent effect of APOE on Alzheimer’s disease and other age-related neurodegenerative disorders. Dis Model Mech2020; 13: dmm045211.
115.
VanaL, KanaanNM, UgwuIC, et al. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Am J Pathol2011; 179: 2533–2550.
116.
TroquierL, CaillierezR, BurnoufS, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res2012; 9: 397–405.
117.
WegielJ, KaczmarskiW, BaruaM, et al. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol2011; 70: 36–50.
118.
CarmonaS, HardyJ and GuerreiroR. The genetic landscape of Alzheimer disease. Handb Clin Neurol2018; 148: 395–408.
119.
VeteleanuA, PapeS, DaviesK, et al. Complement dysregulation and Alzheimer’s disease in Down syndrome. Alzheimers Dement2023; 19: 1383–1392.
120.
CossecJC, LavaurJ, BermanDE, et al. Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Hum Mol Genet2012; 21: 3156–3172.
121.
LeeJH, ChulikavitM, PangD, et al. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer’s disease in adults with Down syndrome. Neurosci Lett2007; 425: 105–109.
122.
Gonzalez-OrtizF, KacPR, BrumWS, et al. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener2023; 18: 18.
123.
KitazawaM, OddoS, YamasakiTR, et al. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci2005; 25: 8843–8853.
124.
BillingsleyML and KincaidRL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J1997; 323: 577–591.
125.
AmadoroG, CorsettiV, CiottiMT, et al. Endogenous Aβ causes cell death via early tau hyperphosphorylation. Neurobiol Aging2011; 32: 969–990.
126.
LeeSY and ChungW-S. The roles of astrocytic phagocytosis in maintaining homeostasis of brains. J Pharmacol Sci2021; 145: 223–227.
127.
LiT, HawkesC, QureshiHY, et al. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3β. Biochemistry2006; 45: 3134–3145.
128.
LiT and PaudelHK. Glycogen synthase kinase 3β phosphorylates alzheimer’s disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry2006; 45: 3125–3133.
129.
JopeRS, YuskaitisCJ and BeurelE. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res2007; 32: 577–595.
130.
SchwalbeM, KadavathH, BiernatJ, et al. Structural impact of tau phosphorylation at threonine 231. Structure2015; 23: 1448–1458.
131.
VerkhratskyA, ParpuraV, Rodriguez-ArellanoJJ, et al. Astroglia in Alzheimer’s disease. Adv Exp Med Biol2019; 1175: 273–324.
132.
ZhouB, ZuoYX and JiangRT. Astrocyte morphology: Diversity, plasticity, and role in neurological diseases. CNS Neurosci Ther2019; 25: 665–673.
133.
HambaliA, KumarJ, HashimNFM, et al. Hypoxia-induced neuroinflammation in Alzheimer’s disease: potential neuroprotective effects of Centella asiatica. Front Physiol2021; 12: 712317.
134.
VangeisonG and RempeDA. The Janus-faced effects of hypoxia on astrocyte function. Neuroscientist2009; 15: 579–588.
135.
FarwaM, NidaI, Muhammad HassanN, et al. Impact of hypoxia on astrocyte induced pathogenesis. In: Thomas H (ed) Neurophysiology. Rijeka: IntechOpen, 2022, pp.Ch.11.
136.
MarcianteAB, HowardJ, KellyMN, et al. Dose-dependent phosphorylation of endogenous Tau by intermittent hypoxia in rat brain. J Appl Physiol 2022; 133: 561–571.
137.
YangC, YangQ, XiangY, et al. The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review. Neural Regen Res2023; 18: 57–63.
138.
RazL, BhaskarK, WeaverJ, et al. Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction. Neurobiol Dis2019; 126: 124–136.
139.
WilsonDM3rd, CooksonMR, Van Den BoschL, et al. Hallmarks of neurodegenerative diseases. Cell2023; 186: 693–714.
140.
PhatnaniH and ManiatisT. Astrocytes in neurodegenerative disease. Cold Spring Harb Perspect Biol2015; 7: a020628.
141.
Rodríguez-GiraldoM, González-ReyesRE, Ramírez-GuerreroS, et al. Astrocytes as a therapeutic target in Alzheimer’s disease-comprehensive review and recent developments. Int J Mol Sci2022; 23: 13630.
142.
Di BenedettoG, BurgalettoC, BellancaCM, et al. Role of microglia and astrocytes in Alzheimer’s disease: from neuroinflammation to Ca(2+) homeostasis dysregulation. Cells2022; 11: 2728.
143.
MatejukA and RansohoffRM. Crosstalk between astrocytes and microglia: an overview. Front Immunol2020; 11: 1416.
144.
BatesBT, ZhangS, DufekJS, et al. The effects of sample size and variability on the correlation coefficient. Med Sci Sports Exerc1996; 28: 386–391.
145.
PajulaJ and TohkaJ. How many is enough? Effect of sample size in inter-subject correlation analysis of fMRI. Comput Intell Neurosci2016; 2016: 2094601.
146.
LanfrancoMF, NgCA and RebeckGW. ApoE lipidation as a therapeutic target in Alzheimer’s disease. Int J Mol Sci2020; 21: 6336.
147.
SienskiG, NarayanP, BonnerJM, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med2021; 13: eaaz4564.
148.
ChungH, GreenPHR, WangTC, et al. Interferon-driven immune dysregulation in Down syndrome: a review of the evidence. J Inflamm Res2021; 14: 5187–5200.
149.
TliliA, HoischenA, RipollC, et al. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients. Mol Neurobiol2012; 46: 297–303.
150.
BellenguezC, CharbonnierC, Grenier-BoleyB, et al. Contribution to Alzheimer’s disease risk of rare variants in TREM2, SORL1, and ABCA7 in cases and controls. Neurobiol Aging2017; 59: 220.e221–220.e229.
151.
CarmonaS, HardyJ and GuerreiroR. Chapter 26 - The genetic landscape of Alzheimer disease. In: GeschwindDH, PaulsonHL and KleinC (eds) Handbook of Clinical Neurology. Elsevier, 2018, pp. 395–408.
152.
BejaninA, IulitaMF, VilaplanaE, et al. Association of Apolipoprotein E varepsilon4 allele with clinical and multimodal biomarker changes of Alzheimer disease in adults with Down syndrome. JAMA Neurol2021; 78: 937–947.
153.
AnelloG, GuéantJ, RomanoC, et al. Allele varepsilon4 of apolipoprotein E gene is less frequent in Down syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. Neurosci Lett2001; 306: 129–131.
154.
JonesEL, MokK, HanneyM, et al. Evidence that PICALM affects age at onset of Alzheimer’s dementia in Down syndrome. Neurobiol Aging2013; 34: 2441.e2441–2445.
155.
PrasherVP, SajithSG, ReesSD, et al. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer’s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry2008; 23: 1134–1140.
156.
LucarelliP, PiciulloA, VerdecchiaM, et al. The role of -850 tumor necrosis factor-alpha and apolipoprotein E genetic polymorphism in patients with Down’s syndrome-related dementia. Neurosci Lett2003; 352: 29–32.
